Clinical Trial: Venetoclax TDM in Newly Diagnosed AML: Exposure-Response and Prognosis

U.S., June 27 -- ClinicalTrials.gov registry received information related to the study (NCT07670130) titled 'Venetoclax TDM in Newly Diagnosed AML: Exposure-Response and Prognosis' on June 19.

Brief Summary: Venetoclax combined with azacitidine (VEN-AZA) is the current first-line standard of care for newly diagnosed acute myeloid leukemia (AML) patients unfit for intensive chemotherapy. Although this regimen substantially improves remission rates, marked inter-individual variability is observed in clinical practice-ranging from severe myelosuppression or tumor lysis syndrome in some patients to poor response or early relapse in others. Venetoclax is primarily metabolized by CYP3A4, and its systemic exposure is modulated by multiple factors...